Posted by Defense World Staff on Aug 18th, 2024
Stock analysts at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT – Get Free Report) in a report released on Sunday. The brokerage set a “hold” rating on the stock.
Several other brokerages also recently issued reports on DBVT. JMP Securities boosted their target price on shares of DBV Technologies from $4.00 to $5.00 and gave the company a “market outperform” rating in a research note on Wednesday, July 31st. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of DBV Technologies in a research report on Thursday, August 1st.
Get Our Latest Stock Analysis on DBV Technologies
DBV Technologies Trading Down 1.3 %
Shares of NASDAQ DBVT opened at $0.93 on Friday. The firm has a 50-day moving average of $0.91 and a two-hundred day moving average of $1.26. The company has a market capitalization of $89.98 million, a price-to-earnings ratio of -1.11 and a beta of 0.68. DBV Technologies has a twelve month low of $0.50 and a twelve month high of $3.70.
DBV Technologies (NASDAQ:DBVT – Get Free Report) last issued its earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. The company had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.42 million. During the same quarter in the previous year, the firm earned ($0.26) earnings per share. As a group, research analysts predict that DBV Technologies will post -1.22 earnings per share for the current year.
Institutional Investors Weigh In On DBV Technologies
A hedge fund recently bought a new stake in DBV Technologies stock. Cowen AND Company LLC acquired a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 50,986 shares of the company’s stock, valued at approximately $49,000. Institutional investors and hedge funds own 71.74% of the company’s stock.
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.
Further Reading
- Five stocks we like better than DBV Technologies
- High Flyers: 3 Natural Gas Stocks for March 2022
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Options Trading – Understanding Strike Price
- MarketBeat Week in Review – 8/12 – 8/16
- 3 Grocery Stocks That Are Proving They Are Still Essential
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for DBV Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for DBV Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.
You might be interested in:
